United Therapeutics (NASDAQ:UTHR) to Provide Business Update at J.P. Morgan Healthcare Conference

United Therapeutics Corporation, a Delaware-based biotechnology company (NASDAQ:UTHR), is set to present an overview of its business and provide updates during the 43rd annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2025. The presentation will include detailed slides, to be incorporated into the event and later posted on the company’s official website at https://ir.unither.com/events-and-presentations.

The scheduled presentation, from 2:15 p.m. to 2:55 p.m. Pacific Standard Time, will also be accessible through a live webcast on the United Therapeutics website, with an archived version available for viewing approximately 24 hours post-presentation. This archived webcast will be available for a 30-day period.

The content shared during this presentation, including the slides attached as Exhibit 99.1, will serve to furnish the audience with an understanding of the company’s current position and future plans. The information being disseminated should not be misconstrued as a “filed” document under the Securities Exchange Act of 1934, nor should it be considered incorporated by reference in future filings under the Securities Act of 1933 or the Exchange Act, regardless of any general language of inclusion in such filings.

Additionally, the company has outlined its intention to exhibit the Investor presentation dated January 13, 2025, under Exhibit 99.1, and the cover page of the Form 8-K in Inline XBRL format as Exhibit 104 in this filing.

United Therapeutics has shown a steady financial foundation with consistent revenue growth, operational cash flow, disciplined financial management practices, and profitability over the years. The company has returned a substantial amount to shareholders, demonstrating a commitment to sustainable success.

Primarily known for its market leadership in the biotech space, United Therapeutics’ innovative approach and robust platform have positioned it as a significant player in the industry. The company’s strategic focus on areas such as rare lung diseases, pediatric oncology, and organ alternatives further solidifies its market presence.

Looking ahead, United Therapeutics lays out a vision that encompasses three waves of growth—Foundation, Innovation, and Revolution. The company aims to progress with a cascade of clinical and regulatory events, including various upcoming studies and potential approvals in the pipeline.

With a sturdy financial footing, market leadership, and a commitment to innovation and patient care, United Therapeutics sets itself apart, uniquely positioned to provide value to both patients and shareholders alike.

United Therapeutics promises a whirlwind of developments as it embarks on a transformative journey over the next three years, asserting its place as a pioneering biotech company in the healthcare landscape.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read United Therapeutics’s 8K filing here.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.